Unlocking the power of pharmacovigilance – An adaptive approach to an evolving drug safety environment (2007)
In this report, HRI evaluates the effect of pharmacogenomics on the life sciences and pharmaceutical industries in the United States, highlighting the clinical impacts. By identifying genetic markers associated with specific conditions, researchers expect to find targets for drugs or therapies to cure diseases, rather than simply alleviate symptoms. This focus includes each step of the process, from clinical trial design to prescribing and monitoring treatment regimens for patients.
Read the report

Global biotech crop acreage increases in 2006 (Jan. 2007)
Read the summaries and press releases

Recapturing the vision: Integrity driven performance in the pharmaceutical industry (2006)
Pharmaceutical companies under are intense pressure to take actions to restore their declining reputations and strengthen the public’s sense of trust in the industry. This report, which is the first in a series of comprehensive reports, explores the reputation issues and compliance challenges facing the industry. We believe the approach outlined in the report provides far-reaching benefits to pharmaceutical companies by enabling them to increase trust and enhance relationships with key stakeholders.
Read the report

Personalized Medicine: The Emerging Pharmacogenomics Revolution (2005)
In this report, PwC evaluates the effect of pharmacogenomics on the life sciences and pharmaceutical industries in the United States, highlighting the clinical impacts. By identifying genetic markers associated with specific conditions, researchers expect to find targets for drugs or therapies to cure diseases, rather than simply alleviate symptoms. This focus includes each step of the process, from clinical trial design to prescribing and monitoring treatment regimens for patients.
Read the report

HealthCast 2020 : Creating a Sustainable Future (2005)
HealthCast 2020, the third in HRI’s flagship HealthCast series, looks at responses around the world to the globalization of the health industry and efforts to create a sustainable health system. Although no one country has all of the solutions, and each country’s health system varies greatly, HRI has identified seven common features for sustainability that include: the need for common ground among stakeholders; a digital backbone; incentive realignment; quality and safety standardization; strategic resource deployment; innovation and process change; and adaptable models of care delivery centered on the needs of patients. Through a survey of more than 580 executives of health industry stakeholders in 27 countries, as well as in-depth interviews with more than 120 health industry leaders in 16 countries, HRI provides transferable lessons of best healthcare practices that cross international borders.
Read the report

"The Economic Status and Performance of Plant Biotechnology in 2003" (Dec. 12, 2003)
by C. Ford Runge, Distinguished McKnight University Professor, University of Minnesota
Read the PDF report

Commerce Department Releases Biotechnology Report (Oct. 24, 2003)
Read the PDF report

Burrill & Company's Biotech 2003 Report
The leading biotechnology industry report
Read the report

Ernst & Young's Global Biotechnology Reports 2003 (June 2003)
Read the reports

Banking on Biotech (June 9, 2003)
A special advertising section reprinted from the June 9 issue of Fortune.
Read the section (213 KB PDF)

Childhood Vaccines: Challenges in Preventing Future Shortages (Sep. 2002)
U.S. Government Accounting Office testimony before the Subcommittee on Public Health, Committee on Health, Education, Labor, and Pensions, U.S. Senate
Read the PDF testimony (70 KB)

Integrating Intellectual Property Rights and Development Policy (Sep. 2002)
At the behest of the British Government, the Commission on Intellectual Property has produced a study exploring the rationale for the current global patent system the impact of that system in a variety of industrial sectors, including agriculture and health.
Read the study

"Top 10 Biotechnologies for Improving Health in Developing Countries" (Sep. 2002)
From the University of Toronto Joint Centre for Bioethics. An international panel of experts identifies 10 genomic and other biotechnologies with the greatest potential for improving global health within a decade, particularly in the world's poorer counties.
Read the PDF report

"100 Years of Bacillus thuringiensis (Bt): A Critical Scientific Assessment." (Sep. 2002)
From the American Academy of Microbiology. This report highlights as a case study Bt and its use in agriculture, as well as addressing the current controversy, benefits and potential risks associated with transgenic plants.
Read the report

"Butterflies and Bt Corn: Allowing Science to Guide Decisions" (Sep. 2002)
USDA Agricultural Research Service and a group of university and organizations: A brochure chronicling the monarch butterfly and Bt corn controversy and how the conclusion was reached that Bt corn pollen does not pose a risk to monarch populations.
Read the brochure

"Animal Biotechnology: Science-Based Concerns." (Aug. 2002)
From the National Academies of Science. The report takes a scientific look at the use and introduction of animal biotechnology for food and protein production.
Read the report

"The Green Century" (Aug. 2002)
From Time Magazine. A special report in the Aug. 26 edition discussing ways to transform industry, timed to coincide with the World Summit on Sustainable Development in Johannesburg, South Africa.
Read online for subscribers or for a fee

"Generic Drug Entry Prior to Patent Expiration" (July 2002)
From the Federal Trade Commission. A report recommending legislative action designed to ensure that two provisions of the Hatch-Waxman amendments do not delay generic drug entry to market. The commission's recommendations would permit only one 30-month stay on the entry of a generic drug during pending patent-infringement litigation and would support new legislation to require brand-name companies and initial generic applicants to provide copies of certain agreements to the FTC and the Department of Justice for review.
Read the PDF report

Beyond Borders: The Global Biotechnology Report 2002 (June 2002)
Ernst & Young surveys the worldwide biotechnology landscape, providing statistics on biotech activity in every major region, as well articles on trends.
Read the executive summary or purchase the complete report
 

"Signs of Life: The Growth of Biotechnology Centers in the U.S." (June 2002)
From the Brookings Institution, Center on Urban and Metropolitan Policy. This report analyzes biotechnology activity in the 51 largest U.S. metropolitan areas and finds that the industry is heavily concentrated in nine regions; Boston, Los Angeles, New York, Philadelphia, Raleigh-Durham, San Diego, San Francisco, Seattle, and Washington-Baltimore.
Read the report

HealthCast Tactics: A Blueprint for the Future (May 2002)
In a landmark research report from the global health industries practice of PricewaterhouseCoopers, health industry leaders identified major gaps in the industry’s ability to meet market demands for performance-based reimbursement, privacy, and clinical excellence. This new report updates the firm’s award-winning 1999 global research report, HealthCast 2010: Smaller World, Bigger Expectations, and suggests tactics for the health industry to employ over the next three to five years. According to HealthCast Tactics, significant gaps exist between what health industry executives, policy makers and employers rate as important and what is being implemented on several important topics. The largest gap identified was in implementing reimbursement systems that reward providers for quality and patient safety. Other critical gaps exist on issues such as administrative efficiency, patient privacy and hospitals providing patient satisfaction data. The report draws on a survey of more than 650 top executives of hospital systems, payers, governments, medical supply vendors, physician groups and employers.
Read the report

HealthCast 2010: Smaller World, Bigger Expectations (November 1999)
HealthCast 2010 is a view of the future from the health industry practice of PricewaterhouseCoopers. To compile this report, PricewaterhouseCoopers commissioned a wide-ranging survey of 380 thought leaders in the United States, the United Kingdom, Finland, Spain, the Netherlands, Germany, France, New Zealand, Canada, and Australia. Those surveyed included a mix of policy makers, health system executives, employers, physicians, insurers and medical supply vendors. In addition, the firm's practice leaders interviewed more than 50 thought leaders from seven countries at length about future trends and their implications for the industry's stakeholders.
Read the report